What can we learn from 2024’s biotech IPOs?
Dec 06, 2024•15 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
After a promising start to the year, the biotech IPO market picked up steam again late this summer, with notable offerings from companies like Upstream, Septerna and BioAge. But what does this mean for the sector? Is market enthusiasm truly returning, or are we just seeing a temporary rebound?
To unpack these questions and look ahead to 2025, Fierce Biotech’s James Waldron chatted with Adam Farlow, Global Chair of Baker McKenzie’s Capital Markets Practice Group.
To learn more about the topics in this episode:
- Septerna's $288M IPO is another sign of the market warming to biotech investment
- BioAge brings in almost $200M from IPO as obesity biotech joins Nasdaq
- Upstream swells IPO to $255M as it prepares to join Nasdaq along with CAMP4
- Kairos goes public with $6M IPO to fund trials of lead cancer drug
See omnystudio.com/listener for privacy information.
For the best experience, listen in Metacast app for iOS or Android